INT1218

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.59
First Reported 1976
Last Reported 2010
Negated 0
Speculated 0
Reported most in Abstract
Documents 24
Total Number 24
Disease Relevance 9.76
Pain Relevance 9.39

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

mitochondrion (Maob) oxidoreductase activity (Maob)
Anatomy Link Frequency
neuronal 2
Maob (Rattus norvegicus)
Pain Link Frequency Relevance Heat
monoamine 62 100.00 Very High Very High Very High
fluoxetine 30 99.84 Very High Very High Very High
Intracerebroventricular 2 99.84 Very High Very High Very High
antidepressant 12 99.78 Very High Very High Very High
Calcium channel 3 99.58 Very High Very High Very High
noradrenaline 13 99.40 Very High Very High Very High
sSRI 3 98.98 Very High Very High Very High
Analgesic 6 98.96 Very High Very High Very High
Inflammation 20 98.90 Very High Very High Very High
palliative 3 98.84 Very High Very High Very High
Disease Link Frequency Relevance Heat
Syndrome 12 99.50 Very High Very High Very High
Attention Deficit Hyperactivity Disorder 3 99.32 Very High Very High Very High
INFLAMMATION 28 98.90 Very High Very High Very High
Disease Progression 3 98.88 Very High Very High Very High
Scrapie 8 98.68 Very High Very High Very High
Ocular Toxicity (including Many Sub-types) 4 98.62 Very High Very High Very High
Disease 48 97.64 Very High Very High Very High
Sleep Disorders 3 97.40 Very High Very High Very High
Dementia 7 97.16 Very High Very High Very High
Pain 6 97.00 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Safinamide (formerly PNU-151774E), a sodium and calcium channel modulator that also inhibits monoamine oxidase B (MAOB), is under development by Newron Pharmaceuticals for the potential treatment of epilepsy, Parkinson's disease (PD), pain and stroke [345222], [348351].
Negative_regulation (inhibits) of MAOB associated with epilepsy, pain, stroke, calcium channel, disease and monoamine
1) Confidence 0.59 Published 2001 Journal Curr Opin Investig Drugs Section Abstract Doc Link 11572661 Disease Relevance 0.72 Pain Relevance 0.20
Selegiline is an irreversible inhibitor of monoamine oxidase B with trophic and neuroprotective effects.
Negative_regulation (inhibitor) of monoamine oxidase B associated with monoamine
2) Confidence 0.57 Published 1998 Journal Neuropharmacology Section Abstract Doc Link 9833630 Disease Relevance 0.23 Pain Relevance 0.68
These results provide evidence for a potential role of monoamine oxidase B inhibition in the therapeutic effects of Prozac.
Negative_regulation (inhibition) of oxidase B associated with monoamine
3) Confidence 0.51 Published 1997 Journal Eur. J. Pharmacol. Section Abstract Doc Link 9389388 Disease Relevance 0 Pain Relevance 0.55
Inhibition of monoamine oxidase B was investigated both in vitro and in vivo in rats by using the radioligand, N-(6-[18F]fluorohexyl)-N-methylpropargylamine ([18F]FHMP).
Negative_regulation (Inhibition) of oxidase B associated with monoamine
4) Confidence 0.51 Published 1997 Journal Eur. J. Pharmacol. Section Abstract Doc Link 9389388 Disease Relevance 0 Pain Relevance 0.46
Safinamide (formerly PNU-151774E), a sodium and calcium channel modulator that also inhibits monoamine oxidase B (MAOB), is under development by Newron Pharmaceuticals for the potential treatment of epilepsy, Parkinson's disease (PD), pain and stroke [345222], [348351].
Negative_regulation (inhibits) of oxidase B associated with epilepsy, pain, stroke, calcium channel, disease and monoamine
5) Confidence 0.51 Published 2001 Journal Curr Opin Investig Drugs Section Abstract Doc Link 11572661 Disease Relevance 0.72 Pain Relevance 0.19
Rasagiline is a monoamine oxidase-B inhibitor that has demonstrated efficacy against the cardinal symptoms of Parkinson's disease when used as monotherapy in early Parkinson's disease, and as an adjunct to levodopa in advanced disease stages.
Negative_regulation (inhibitor) of oxidase-B associated with disease and monoamine
6) Confidence 0.46 Published 2005 Journal Expert Opin Pharmacother Section Abstract Doc Link 16197359 Disease Relevance 1.37 Pain Relevance 0.15
These effects were associated with marked decreases in type A (clorgyline) or type A and B monoamine oxidase activity (tranylcypromine and 4-fluorotranylcypromine).
Negative_regulation (decreases) of B monoamine oxidase associated with monoamine
7) Confidence 0.45 Published 1988 Journal Eur. J. Pharmacol. Section Abstract Doc Link 2846327 Disease Relevance 0 Pain Relevance 0.27
Effects of a selective monoamine oxidase (MAO)--A inhibitor, clorgyline, a selective MAO-B inhibitor, deprenyl, and a non-selective MAO inhibitor, nialamide, were investigated on footshock-induced aggression (FIA) in paired rats.
Negative_regulation (inhibitor) of MAO-B associated with aggression and monoamine
8) Confidence 0.43 Published 1990 Journal Indian J. Exp. Biol. Section Abstract Doc Link 2123820 Disease Relevance 0.32 Pain Relevance 0.12
An analgesic effect of enkephalinase inhibition is modulated by monoamine oxidase-B and REM sleep deprivations.
Negative_regulation (deprivations) of monoamine oxidase-B associated with pain, analgesic and monoamine
9) Confidence 0.42 Published 1986 Journal Naunyn Schmiedebergs Arch. Pharmacol. Section Title Doc Link 3090452 Disease Relevance 0.16 Pain Relevance 0.92
Furthermore, inhibitors of MAO-B do not have any curative or palliative effect on this experimental model indicating that the raise of this activity is probably more a consequence rather than a causal event of the neurodegenerative process.
Negative_regulation (inhibitors) of MAO-B associated with neurodegenerative disease and palliative
10) Confidence 0.38 Published 2008 Journal Neurochem. Int. Section Abstract Doc Link 18442871 Disease Relevance 0.82 Pain Relevance 0.17
Regarding these results, MAO-B could be a potential therapeutic target then we have performed a pre-clinical treatment with irreversible (Selegiline or L-deprenyl) or and reversible (MS-9510) MAO-B inhibitors used alone or in association with an anti-scrapie drug such as MS-8209, an amphotericin B derivative.
Negative_regulation (inhibitors) of MAO-B associated with scrapie
11) Confidence 0.38 Published 2008 Journal Neurochem. Int. Section Abstract Doc Link 18442871 Disease Relevance 0.88 Pain Relevance 0.17
Evaluation of monoamine oxidase B inhibition by fluoxetine (Prozac): an in vitro and in vivo study.
Negative_regulation (inhibition) of oxidase B associated with fluoxetine and monoamine
12) Confidence 0.37 Published 1997 Journal Eur. J. Pharmacol. Section Title Doc Link 9389388 Disease Relevance 0 Pain Relevance 0.60
Reserpine-induced ptosis was reversed by rasagiline at doses above 2 mg x kg(-1) i.p., which inhibit MAO-A as well as MAO-B, but not at MAO-B-selective doses.
Negative_regulation (inhibit) of MAO-B associated with ocular toxicity (including many sub-types)
13) Confidence 0.30 Published 2002 Journal Neuropharmacology Section Abstract Doc Link 12504917 Disease Relevance 0.44 Pain Relevance 0.46
However, combination of rasagiline (10 mg x kg(-1) i.p.) with L-DOPA or L-tryptophan (50 mg x kg(-1) i.p.), or rasagiline (10 mg x kg(-1) p.o.) with fluoxetine (10 mg x kg(-1) p.o.), did not induce the behavioural hyperactivity syndrome which is seen following inhibition of both MAO-A and MAO-B by tranylcypromine together with the monoamine precursors.
Negative_regulation (inhibition) of MAO-B associated with syndrome, attention deficit hyperactivity disorder, monoamine and fluoxetine
14) Confidence 0.30 Published 2002 Journal Neuropharmacology Section Abstract Doc Link 12504917 Disease Relevance 0.44 Pain Relevance 0.69
The elimination of deprenyl, a MAO-B inhibitor, used for the treatment of the early stage of Parkinson’s disease and senile dementia was investigated using thin layer chromatography.
Negative_regulation (inhibitor) of MAO-B associated with dementia and disease
15) Confidence 0.29 Published 2008 Journal The Open Medicinal Chemistry Journal Section Abstract Doc Link PMC2709476 Disease Relevance 0.68 Pain Relevance 0
Rasagiline does not modify CNS monoamine tissue levels or monoamine-induced behavioural syndromes at doses which selectively inhibit MAO-B but not MAO-A.
Negative_regulation (inhibit) of MAO-B associated with syndrome and monoamine
16) Confidence 0.22 Published 2002 Journal Neuropharmacology Section Abstract Doc Link 12504917 Disease Relevance 0.42 Pain Relevance 0.64
Our aim was to study fracture risk in users of various antidepressants (tricyclic antidepressants, selective serotonin reuptake inhibitors, and the group of other antidepressants including monoamine oxidase B inhibitors and drugs with effect on the norepinephrine system) and its relationship with effects on inhibition of the cholinergic and serotonin transporter system.
Negative_regulation (inhibitors) of monoamine oxidase B associated with antidepressant, serotonin, ssri, tricyclic antidepressant and monoamine
17) Confidence 0.21 Published 2008 Journal Calcif. Tissue Int. Section Abstract Doc Link 18219438 Disease Relevance 0 Pain Relevance 0.54
The pharmacological properties of kava are postulated to include blockade of voltage-gated sodium ion channels, enhanced ligand binding to gamma-aminobutyric acid (GABA) type A receptors, diminished excitatory neurotransmitter release due to calcium ion channel blockade, reduced neuronal reuptake of noradrenaline (norepinephrine), reversible inhibition of monoamine oxidase B and suppression of the synthesis of the eicosanoid thromboxane A(2), which antagonises GABA(A) receptor function.
Negative_regulation (inhibition) of monoamine oxidase B in neuronal associated with neurotransmitter, gaba, noradrenaline and monoamine
18) Confidence 0.13 Published 2002 Journal CNS Drugs Section Abstract Doc Link 12383029 Disease Relevance 0.90 Pain Relevance 0.49
Pre-treatment with pargyline, an inhibitor of monoamine oxidase B, is useful for this assessment, as it induces the accumulation of t-MH in the extraneuronal space (Oishi et al. 1987; Oohara et al. 1994, 1994).
Negative_regulation (inhibitor) of monoamine oxidase B associated with monoamine
19) Confidence 0.12 Published 2007 Journal Journal of Neurochemistry Section Body Doc Link PMC2156111 Disease Relevance 0 Pain Relevance 0.05
Rats were pre-treated with pargyline hydrochloride (0.33 mmol/kg, i.p.), an inhibitor of monoamine oxidase B which induced accumulation of tete-methylhistamine (t-MH) in the extraneural space as a major metabolite of released neuronal histamine 90 min before the central infusion of either TRH (100 nmol/10 ?
Negative_regulation (inhibitor) of monoamine oxidase B in neuronal associated with monoamine
20) Confidence 0.12 Published 2007 Journal Journal of Neurochemistry Section Body Doc Link PMC2156111 Disease Relevance 0 Pain Relevance 0.05

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox